**Piperacillin + tazobactam**

**Section:** 6. Anti-infective medicines 〉 6.2. Antibacterials 〉 6.2.1. Access group antibiotics

### Indication
Necrotising fasciitis  
**ICD11 code:** E1871.2

### INN
Piperacillin + tazobactam

### Medicine type
Chemical agent

### Antibiotic groups
WATCH

### List type
Core

### Formulations
Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

### EML status history
- First added in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

### Sex
All

### Age
Also recommended for children

### Therapeutic alternatives
The recommendation is for this specific medicine

### Patent information
Patents have expired in most jurisdictions
Read more about patents.

### Wikipedia
Piperacillin + tazobactam

### DrugBank
Piperacillin, Tazobactam

---

**Expert Committee recommendation**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:

- the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.
- replacing the oral liquid formulation of clindamycin (oral liquid 75 mg/5 mL) with powder for oral liquid 75 mg/5 mL (as palmitate hydrochloride) on the EML and EMLc.
- the addition of new strength formulations of IV vancomycin (500 mg, 1 g (as hydrochloride) on the EMLc.

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended that the range of strengths of metronidazole tablets be replaced with reference to specific strengths on the EML and EMLc.

**EML recommendations: Necrotising fasciitis**

**First choice**

- metronidazole
  - co-prescribed with ceftriaxone

**Second choice**

- clindamycin
  - co-prescribed with piperacillin + tazobactam
- vancomycin